Industry seeks US FDA guidance on validating REMS tools
This article was originally published in Scrip
Executive Summary
The pharmaceutical industry is looking to the US FDA for guidance in validating new tools for risk evaluation and mitigation strategies (REMS), speakers said at the recent Food and Drug Law Institute annual meeting in Washington, DC.